You are here

FDA Approves Metoprolol Tartrate in New 25mg Dose

PITTSBURGH--(BUSINESS WIRE)--Jan. 22, 2004--Mylan Laboratories Inc. (NYSE:MYL - News) today announced that the U.S. Food and Drug Administration has granted final approval for Mylan Pharmaceuticals' Abbreviated New Drug Application, which provides for a new strength (25 mg) of metoprolol tartrate.

President and COO, Louis J. DeBone stated, "Mylan is the single largest generic supplier of metoprolol tartrate, in 50 mg and 100 mg strengths, in the United States. The addition of a new 25 mg strength further enhances our generic product portfolio and offers a convenient dosage alternative for patients and health care providers."

The new 25 mg product will be available soon.

Source: Mylan Laboratories Inc.

Recent Headlines

NY Hospitals Required to Implement Protocols in Suspected Cases
Presence of BOK Protein Key for Positive Treatment Response
Patient Access to Inhaler Use Data Could Improve Asthma Management
Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens
Primary Immunodeficiencies Affect 250,000 People in U.S.
More Than 25% of Patients Responded to Xpovio/Dexamethasone Combo
Attacks Cancerous Cells, Leaves Healthy Tissues Alone
Moderates Pre-diabetes Progression, Reduces Cholesterol Levels